BridgeBio Oncology Therapeutics, Inc.
BBOT
$11.30
$0.232.08%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 696.00% | 94.79% | 9.78% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 150.11% | 26.07% | 49.76% | ||
| Operating Income | -150.11% | -26.07% | -49.76% | ||
| Income Before Tax | -158.37% | -30.30% | -42.82% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -158.37% | -30.30% | -42.82% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -158.37% | -30.30% | -42.82% | ||
| EBIT | -150.11% | -26.07% | -49.76% | ||
| EBITDA | -150.40% | -26.05% | -49.92% | ||
| EPS Basic | 99.93% | 71.22% | 56.20% | ||
| Normalized Basic EPS | 99.93% | 71.22% | 56.20% | ||
| EPS Diluted | 99.93% | 71.22% | 56.20% | ||
| Normalized Diluted EPS | 99.93% | 71.22% | 56.20% | ||
| Average Basic Shares Outstanding | 391,711.71% | 352.77% | 226.14% | ||
| Average Diluted Shares Outstanding | 391,711.71% | 352.77% | 226.14% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||